Sustainable Supply Chain

In Taiwan’s regenerative cell industry chain, upstream companies are engaged in the collection and preservation of stem cells and tissues, including materials such as newborn umbilical cord blood, bone marrow, umbilical cords, and fertilized eggs. After legally obtaining the cells, they are processed through standard operating procedures such as separation, testing, and cryopreservation to ensure they remain uncontaminated and maintain long-term biological functions for therapeutic use.

Midstream companies develop functional products from the aforementioned stem cells and tissues. Their operations include cell thawing, cell purification, database establishment for search and matching, sample transportation, and cell transplantation.

In the downstream segment of the regenerative cell industry chain, stem cells and immune cells are applied to immunotherapy, drug development, and basic research. Stem cells can be used to cultivate autologous stem cells for repairing damaged tissues, while immune cells are used to treat cancer and autoimmune diseases.

Medigen is positioned in the downstream sector of the regenerative cell industry chain. Through close collaboration with major hospitals, patient-derived cells are transported to Medigen’s laboratories, where they are cultured using specialized techniques before being injected back into the patient’s body to mitigate immune rejection in allogeneic treatments.